Grace Therapeutics, Inc. (GRCE)
EBITDA Growth
-411.27%
Quarterly · Period ending:
GRCE EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported-411.27%period ending
Latest reported-411.27%period ending
GRCE Quarterly EBITDA YoY % (-100.35% → -411.27%)
Year-over-year change
High-resolution chart · PNG
GRCE ebitda growth history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | EBITDA Growth |
|---|---|
| -411.2694% | |
| 33.612% | |
| 36.9475% | |
| 26.9772% | |
| 54.4982% | |
| -2.3497% | |
| -32.0451% | |
| -70.5728% | |
| -72.8518% | |
| 21.3033% | |
| 29.1773% | |
| 45.2302% | |
| 33.7147% | |
| -2.2515% | |
| -5.7398% | |
| -14.3664% | |
| -23.1342% | |
| 38.2486% | |
| -68.1588% | |
| -3.6239% | |
| 29.3667% | |
| -125.1157% | |
| 72.0946% | |
| 78.759% | |
| 17.038% | |
| 384.9187% | |
| -311.8391% | |
| -20.8772% | |
| -62.4508% | |
| -126.9556% | |
| 34.0905% | |
| -462.2595% | |
| -225.3475% | |
| -219.8045% | |
| -130.7515% | |
| 13.798% | |
| -11.2264% | |
| -168.819% | |
| -494.063% | |
| 39.6271% | |
| -137.8517% | |
| 83.0566% | |
| -116.9684% | |
| 25.5079% | |
| 226.5773% | |
| -10.8023% | |
| 202.4358% | |
| -29.6665% | |
| -70.6479% | |
| -62.4687% | |
| -27.6297% | |
| -4.5626% | |
| 26.388% | |
| -0.6597% | |
| -56.0297% | |
| -52.4406% | |
| -231.5347% | |
| -225.8293% | |
| -149.8388% | |
| -143.1794% | |
| -58.0155% | |
| -8.2405% | |
| -33.3761% | |
| -100.3487% |